XTL Biopharmaceuticals Ltd Market Cap ($1.19 Million)
Market Cap & Net Worth: XTL Biopharmaceuticals Ltd (H2K2)
XTL Biopharmaceuticals Ltd market cap. XTL Biopharmaceuticals Ltd (F:H2K2) has a market capitalization of $1.19 Million (€1.02 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #30548 globally and #2663 in its home market, demonstrating a 408.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying XTL Biopharmaceuticals Ltd's stock price €2.28 by its total outstanding shares 2365608 (2.37 Million). Also see H2K2 cash flow metrics for how efficiently the company converts equity into cash flow.
XTL Biopharmaceuticals Ltd Market Cap History (2015–2026)
XTL Biopharmaceuticals Ltd market cap history from 2015 to 2026. Data shows change from $18.50 Million to $6.31 Million (-11.07% CAGR). Check today's stock price for XTL Biopharmaceuticals Ltd for real-time trading data and today's change.
XTL Biopharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how XTL Biopharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore H2K2 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
11.84x
XTL Biopharmaceuticals Ltd's market cap is 11.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $5.34 Million | $451.00K | -$1.03 Million | 11.84x | N/A |
Competitor Companies of H2K2 by Market Capitalization
Companies near XTL Biopharmaceuticals Ltd in the global market cap rankings as of November 4, 2026. Also see H2K2 asset base for a full breakdown of the balance sheet.
Key companies related to XTL Biopharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of XTL Biopharmaceuticals Ltd (2015–2026)
Market capitalization of XTL Biopharmaceuticals Ltd from 2015 to today. Between 2015 and today, XTL Biopharmaceuticals Ltd's market cap moved from $18.50 Million to $ 6.31 Million, with a yearly change of -11.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €6.31 Million | +342.72% |
| 2025 | €1.42 Million | -73.32% |
| 2024 | €5.34 Million | +125.73% |
| 2023 | €2.36 Million | -20.09% |
| 2022 | €2.96 Million | -55.42% |
| 2021 | €6.64 Million | -8.40% |
| 2020 | €7.25 Million | +136.04% |
| 2019 | €3.07 Million | -26.49% |
| 2018 | €4.18 Million | -20.78% |
| 2017 | €5.27 Million | -27.25% |
| 2016 | €7.25 Million | -60.84% |
| 2015 | €18.50 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of XTL Biopharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.19 Million USD |
| MoneyControl | $1.19 Million USD |
| MarketWatch | $1.19 Million USD |
| marketcap.company | $1.19 Million USD |
| Reuters | $1.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About XTL Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more